Chęciny
Chęciny
Chęciny, Poland8 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 3 | 2026-10-02 | NCT06283966 | |
| Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 3 | 2026-10-01 | NCT07190222 | |
| Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment | Eosinophilia, Granuloma, Hemic and Lymphatic Diseases, Hypersensitivity, Immediate, Respiratory Hypersensitivity, Skin and Connective Tissue Diseases, anti-neutrophil cytoplasmic antibody-associated vasculitis, asthma, autoimmune disease, bronchial disorder, cardiovascular disorder, eosinophilic granulomatosis with polyangiitis, hematologic disorder, hypereosinophilic syndrome, immune system disorder, leukocyte disorder, lung disorder, lymphatic system disorder, lymphoproliferative syndrome, necrotizing vasculitis, obstructive lung disease, respiratory system disorder, skin disorder, skin vascular disease, vascular disorder, vasculitis | Recruiting | Phase 3 | 2026-09-22 | NCT07444567 | |
| Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma | Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Phase 2 | 2026-09-22 | NCT06676319 | |
| Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma | Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Enrolling by invitation | Phase 2 | 2026-09-21 | NCT06609239 | |
| A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 2 | 2026-09-09 | NCT07082738 | |
| Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial | Eosinophilia, Hemic and Lymphatic Diseases, hematologic disorder, hypereosinophilic syndrome, leukocyte disorder | Recruiting | Phase 3 | 2026-09-04 | NCT05334368 | |
| A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) | Eosinophilia, Hemic and Lymphatic Diseases, hematologic disorder, hypereosinophilic syndrome, leukocyte disorder | Active, not recruiting | Phase 3 | 2026-07-10 | NCT04191304 |